LISCURE BIOSCIENCES
LISCure Biosciences is a developer of bacteria-mediated immunotherapy designed to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases. The company currently has seven pipelines of medicine and two pipelines of health-functioning food and is considering the introduction of two more pipes.
LISCURE BIOSCIENCES
Industry:
Biotechnology Health Care
Founded:
2018-12-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.liscure.bio
Total Employee:
1+
Status:
Active
Contact:
02-3443-1800
Total Funding:
5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apache Mobile Non Scaleable Content Google Apps For Business Cloudflare JS CDN JS AJAX Libraries API
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Current Employees Featured
Hwaseop Chin Co-Founder & Chief Executive Officer @ LISCure Biosciences
Co-Founder & Chief Executive Officer
2018-12-01
Junyoung Kil Chief Financial Officer @ LISCure Biosciences
Chief Financial Officer
2018-12-01
Founder
Investors List
KB Securities
KB Securities investment in Seed Round - LISCure Biosciences
Shinhan Investment
Shinhan Investment investment in Seed Round - LISCure Biosciences
NHN Investment
NHN Investment investment in Seed Round - LISCure Biosciences
Official Site Inspections
http://www.liscure.bio Semrush global rank: 4.34 M Semrush visits lastest month: 986
- Host name: 183.111.169.45
- IP address: 183.111.169.45
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
Cannot get whois informations of this domain!!!
More informations about "LISCure Biosciences"
LISCure
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancerimmunotherapy” and “oral microbiome therapeutics.” The LMT (LISCure …See details»
LISCure Biosciences - Crunchbase Company Profile
LISCure Biosciences is a biotech company that researches and develops bacteria-mediated immunotherapy. View contacts for LISCure Biosciences to access new leads and connect with decision-makers.See details»
LISCure
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.”See details»
LISCure
LISCure Biosciences is a clinical-stage pharmaceutical company focusing on “injectable bacteria-mediated cancer immunotherapy” and “oral microbiome therapeutics.” LISCure is developing …See details»
LISCure Biosciences Company Profile 2024: Valuation, …
Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer.See details»
LISCure Biosciences Inc. - LinkedIn
LISCure is a clinical-stage biotherapeutic company focused on developing bacteria-mediated immunotherapy using a single strain approach for major therapeutic areas. The company focuses on...See details»
LISCure Biosciences Announces FDA Clearance of IND Application …
Feb 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as …See details»
LISCure Biosciences receives U.S. FDA Fast Track designation for …
Mar 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs and drug delivery platforms based on innovative modalities for the areas with high …See details»
LISCure Biosciences Announces FDA Clearance of IND Application …
Feb 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as …See details»
LISCure
Mar 4, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs based on innovative modalities for the areas of high unmet medical needs such as …See details»
LISCure's Phase 2 Drug Candidate Granted Orphan Drug …
SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), …See details»
Celltrion and LISCure Biosciences announce strategic collaboration …
SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ — LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a …See details»
LISCure, the first Korean biotech company receiving equity …
Jul 26, 2021 · LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to …See details»
LISCure Biosciences receives U.S. FDA Fast Track designation for …
Mar 29, 2024 · LISCure Biosciences Inc. is a clinical-stage company developing microbe-oriented new drugs and drug delivery platforms based on innovative modalities for the areas with high …See details»
LISCure Biosciences announces research collaboration with Mayo …
Jan 6, 2022 · LISCure has been conducting joint research with Mayo Clinic for NASH drugs since 2021, and this new collaboration is an agreement signed under the leadership of Nicholas F. …See details»
LISCure
We plan to develop personalized therapeutics by analyzing the gut microbiome, individual immunity, and metabolite profiles using this platform.See details»
LISCure Biosciences Announces Oral Presentation of New Drug …
SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative …See details»
LISCure Biosciences Announces FDA Clearance of IND Application …
Feb 29, 2024 · LISCure has its own screening platform technology based on a proprietary in-house microorganism bank and is dedicated to developing first-in-class new drugs against …See details»
LISCure Bioscience Co. Ltd. (LISCure Bioscience Co. Ltd.) - 药物管 …
The US Food and Drug Administration (FDA) has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the treatment of primary sclerosing cholangitis …See details»
LISCure
Dec 9, 2022 · LISCure, through research collaboration with Mayo Clinic, has demonstrated therapeutic efficacy in PSC in animal models. Global Pharmaceutical companies have been …See details»